Published: 2021-09-08 07:55 | Updated: 2021-09-08 07:54

Current calls, week 36, 2021

Tips from KI Grants Office about current calls.

Swedish and Nordic calls

Anslag för genetisk forskning - Erik Philip-Sörensens stiftelse för främjande av genetisk och humanistisk vetenskaplig forskning

Stiftelsen önskar stödja framtidsinriktad forskning av välmeriterade forskare och forskningsgrupper. Vi välkomnar speciellt ansökningar från yngre post-doc forskare som önskar att utveckla nya forskningsteman. Anslag utdelas normalt ej till odisputerade forskare. Storleken på de beviljade anslagen ligger normalt mellan 50.000 och 400.000 kr.

Closing date: 19 September 2021

Further information

Scholarship for genetic research – Marcus Borgström’s foundation for genetic research, Uppsala University

Support research related to genetics with a special interest in human genetics. Young researchers building their research resources enjoy precedence. Researchers at Uppsala University, Lund University, Stockholm University and Karolinska Institutet can apply for scholarships.

Closing date: 22 September 2021

Further information

K och O F Hedströms stiftelse

Ej fastställt antal stipendier med utlyst belopp 60 000 kr (totalsumma)

Observera: Företräde ges yngre forskare som bygger upp sin forskningsverksamhet. Om medel erhållits tidigare ska resultat redovisas. Stipendier kan sökas av forskare vid Uppsala universitet, Lunds universitet, Stockholms universitet och Karolinska institutet.

Till genetisk forskning företrädesvis humangenetik vid universiteten i Uppsala, Lund och Stockholm samt vid Karolinska institutet, i första hand till svensk forskare för forskning i eller utom Sverige, i andra hand till utländsk forskare för forskning i Sverige. Utdelas av rektor efter förslag av en särskild nämnd.

Closing date: 22 September, 2021

Further information

Forskningspris i idrottsvetenskap - Sveriges Centralförening för Idrottens Främjande

Priser tilldelas en erfaren forskare och en yngre forskare i syfte att stimulera fortsatt forskning inom idrottsvetenskap. Institutioner och enskilda personer kan nominera. Självnominering accepteras. Juryn kan inom sig nominera kandidater. Ett pris värt SEK 100,000 till en erfaren forskare samt ett pris värt SEK 50,000 till en yngre forskare, finns tillgängliga.

Closing date: 30 September 2021

Further information

Forskningsanslag - Cancer- och Allergifonden.

Fondens ändamål är att främja vetenskaplig forskning om miljörelaterade cancer- och allergisjukdomar samt att ge stöd till dem som behöver det som mest; de svårt sjuka som fått sin ekonomi raserad av sjukdomen.

Closing date: 30 September 2021

Further information

Forskningsanslag - Parkinson Research Foundation

Stiftelsen har som ändamål att främja forskning för utveckling av behandlingar med syfte att bromsa eller bota Parkinsons sjukdom och andra neurodegenerativa sjukdomar. Stiftelsen ska också stödja forskning som resulterar i ny kunskap om orsaker till att individer utvecklar Parkinsons sjukdom och andra neurodegenerativa sjukdomar.

Closing date: 1 October 2021

Further information

Wenner-Gren stiftelsernas stipendier

  • Postdoktorstipendier för utbildning i Sverige (utländska postdoktorer): Stipendierna är avsedda att möjliggöra för utländska disputerade forskare att verka vid svensk vetenskaplig institution.
  • Gästforskarstipendier: Stipendierna är avsedda att underlätta för utländska seniora forskare att verka i Sverige.
  • Sabbatsstipendier: Stipendierna är avsedda att möjliggöra för svensk senior forskare, vanligen professor, att verka vid utländsk vetenskaplig institution.
  • Resestipendier: Stipendierna är avsedda för kortare tids besök utomlands för aktivt deltagande i internationella kongresser, symposier, workshops och kurser. Medel ges inte för forskningsvistelser utomlands.

Closing date: 1 October 2021

Further information

New and improved biological drugs in healthcare - Vinnova

Supports innovate collaborative projects that will develop or improve biological drugs or make the drugs easier to use or more easily accessible in healthcare and for patients. Grants are worth up to SEK 5 million for two to three years.

Closing date: 2 November 2021

Further information

European calls

ERC-2022-SyG synergy grants -- Horizon Europe: Excellent Science, EU and other funders

These enable groups of 2-4 principal investigators and their teams to bring together complementary skills, knowledge, and resources in new ways to jointly address ambitious research problems. The aim is to promote scientific advances, to cross-fertilise scientific fields, and to encourage new productive lines of enquiry and new methods and techniques, including unconventional approaches and investigations at the interface between established disciplines. Proposals will be evaluated on the sole criterion of scientific excellence, including outstanding intrinsic synergetic effect.

Applicants may be researchers of any age or nationality. Each principal investigator must present an internationally competitive early achievement track-record or a 10-year track record. One of the principal investigators, as well as team members of any principal investigator, may be hosted and engaged by an institution outside the EU member states or associated countries.

Approximately 33 grants are available, each worth up to €10m over six years. An additional €4m can be requested under certain circumstance.

If you are interested in applying for an ERC Synergy Grant, please contact Tamsin Lindström at Grants Office.

Closing date: 10 November 2021

Further information

Research training fellowships - European Society for Paediatric Infectious Diseases, EUR

The European Society for Paediatric Infectious Diseases invites applications for its research training fellowships. These fund visits by ESPID members to other centres to obtain experience or training in techniques or areas not otherwise available to them. Clear and specific training objectives, which could involve clinical, laboratory, public health or other academic areas, are essential.

Budget: The awards will cover 3 areas.

  • Travel costs (round trip) with a fixed maximum budget as per ESPID guidelines.
  • Accommodation to a maximum of Eur300 per week with receipts.
  • Subsistence to a maximum of Eur120 per week (no receipts required).
  • The host centre can claim fixed funding towards their costs (Eur80 fixed sum for administration expenses, plus a maximum of Eur180 per week to cover infrastructure costs) and will not be made to individuals.


  • Must be “good standing” ESPID member at the time of the deadline (click here to download the ESPID "good standing" member criteria) and current membership fees must be paid up in full before your application.
  • Must be a trainee paediatrician or in medical, allied health professional or scientific training in a clinical or academic centre involved in paediatrics or child health.
  • Applications from those in career posts may also be funded if there is a clear case that the relevant experience to be gained is of strategic importance and not available locally.

Closing date: 31 December 2021

Further information 

Postdoctoral research fellowship exchange programme - European Committee for Treatment and Research in Multiple Sclerosis, CH

ECTRIMS offers a postdoctoral research fellowship exchange programme for young neuroscientists to facilitate their conduct of and training in basic, clinical or applied research related to multiple sclerosis (MS). The goal of the programme is to maximize exchange of information and to help grow the pool of well-trained research scientists focused on problems in MS. Initially, it is anticipated that several fellowships will be awarded each year.

Budget: €55’000 per year. Fellowships of 1 or 2 years duration will be available. ECTRIMS will also provide economy round-trip transportation from the successful candidate’s home location to the training site (no travel expenses for family members).


  • Scientists and physicians who hold or are candidates for an MD, PhD, ScD or equivalent professional degree
  • Candidates must have received their advanced degree(s) prior to initiation of the fellowship.
  • At the time of application fellows should have no more than one year of prior postdoctoral training at the same host institution/mentor.
  • More senior candidates may have no more than 5 years total of postdoctoral experience beyond their final degree (PhD, MD, ScD or equivalent) at the time of application.
  • Successful applicants will be less than 40 years of age at the time of application; exceptions under special circumstances will be considered.
  • Postdoctoral research training must be undertaken in a European laboratory or clinic.
  • Candidates and their mentors must affirm that there will be no language barriers that will impede the training experience.

Closing date: 1 December 2021

Further information 

New targets for diabetes or obesity-related metabolic diseases - European Association for the Study of Diabetes, EUR

The European Association for the Study of diabetes invites applications for its new targets for diabetes or obesity-related metabolic diseases call. This stimulates research focusing on the identification and molecular understanding of new targets for the treatment of type 2 diabetes or obesity-related metabolic diseases.

Budget: Up to Euro 100,000. The duration of each award may be one year or longer, depending upon the needs of the project and as justified in the application.


  • The PI and any co-investigators must be employed full-time by their host institute.
  • Principal investigators must be paid-up EASD members.

Closing date: 1 December 2021, 12:00 midday (CET)

Further information 

Sheila Sherlock postgraduate fellowship - European Association for the Study of the Liver, EUR

The European Association for the Study of the Liver invites applications for the Sheila Sherlock postgraduate fellowship. This supports newly qualified postgraduate researchers who wish to expand research fields and start developing their independent research careers at a European center.

Budget: This two-year full-time fellowship provides:

  • base salary funding of EUR 60,000 per year
  • mobility allowance of EUR 500 per month
  • family allowance of EUR 500 per month for eligible candidates

Eligibility: Applicants must

  • hold a PhD and/or a MD degree
  • have no more than two years of postgraduate research experience
  • be active EASL members or have applied for membership at the time of the application
  • No more than 1 application per home institution during the period of 2 years following the grant award.
  • The research supervisor(s) in the hosting institution must be EASL member(s) but must not be member(s) of the EASL Governing Board

Closing date: 15 December 2021

Further information 

US calls

Federal Funding agencies

Research on current topics in Alzheimer's disease and its related dementias (R01, R21 clinical trial optional), NIH

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing new tests, animal models, techniques, etc. to advance research on Alzheimer's disease and its related dementias. Further information on the high-priority topics of interest are announced through a series of Notices published in connection to this FOA.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of similar scientific scope, PAR-19-071, which solicits applications under the NIH exploratory/developmental (R21) grant mechanism.

Closing date: November 12, 2021, by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement (FOA):  PAR-19-070 (R01), PAR-19-071 (R21)

Further information (R01)

Further information (R21)

Advancing genomic medicine research (R01, R21 clinical trial optional), NIH

This Funding Opportunity Announcement (FOA) encourages applications that stimulate innovation and advance understanding of when, where, and how best to implement the use of genomic information and technologies in clinical care. Proposed projects should be broadly applicable to genomic medicine as a field, and yield findings of significance beyond a single disease, gene, or setting. Projects are strongly encouraged to include ancestrally diverse and underrepresented participants and populations.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, RFA-HG-20-037, which solicits applications under the NIH exploratory or developmental research (R21) grant mechanism.

Closing date: November 2, 2021; August 1, 2022; March 13, 2023. Letter of Intent Due Date: 30 days prior to the application due date. All applications are due by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement (FOA): RFA-HG-20-036 (R01), RFA-HG-20-037 (R21)

Further information (R01)

Further information (R21)

Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R01 Clinical Trial Optional), NIH

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to advance our understanding of: the modes of transmission of Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8); the biology of the initial steps of infection; and the risk factors for infection. Such studies should inform and advance efforts to reduce or eliminate KSHV transmission and thus prevent Kaposi sarcoma (KS), KSHV-associated multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and other KSHV-induced diseases in populations living with HIV or at high risk of HIV infection.

Closing date: December 14, 2021. Letter of Intent Due Date: 30 days prior to the application due date. All applications are due by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement (FOA): RFA-CA-20-046

Further information 

Novel approaches to safe, non-invasive, real time assessment of human placenta development and function across pregnancy (R01, R21 clinical trial not allowed), NIH

This Funding Opportunity Announcement (FOA) invites grant applications that use novel approaches for the development of safe, real-time, non-invasive (or minimally invasive), in vivo methods to assess the development and function of the human placenta across pregnancy. Proposed tools and technologies may address the following:

  • anatomic and structural changes of the placenta across development;
  • villous cell structure and function;
  • blood flow, oxygenation, diffusion and perfusion within the placenta;
  • maternal-foetal nutrient transfer across the placenta;metabolic changes within the placenta including oxygenation, oxidative stress, choline, lipids and lactate, and including measures of placental proteins and gene expression;
  • placental targeted or regional barrier, permeability and function in the human placenta;
  • regulation of maternal and fetal immunologic function involved in placental processes.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, PA-18-885, which solicits applications under the NIH exploratory/developmental (R21) grant mechanism.

Closing date: December 6, 2021, by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement (FOA): PAR-18-884 (R01), PAR-18-885 (R21)

Further information (R01)

Further information (R21)


Technology Impact Award, Cancer Research Institute, US

The Cancer Research Institute Technology Impact Award provides seed funding to address the gap between technology development and clinical application of cancer immunotherapies. These grants aim to encourage collaboration between technology developers and clinical cancer immunologists and to generate the proof-of-principle of a novel platform technology in bioinformatics, ex vivo or in silico modeling systems, immunological or tumor profiling instrumentation, methods, reagents and assays, or other relevant technologies that can enable clinician scientists to generate deeper insights into the mechanisms of action of effective or ineffective cancer immunotherapies.

Award winners will be selected based on the novelty, creativity, technical sophistication, and transformative potential of the technology to impact cancer immunotherapy research around the world. The ultimate aim of this program is to advance technologies that can speed up the entire field’s efforts in addressing one of the most defining challenges of our time—developing immunotherapies that are effective for all cancer patients.

Applicants must hold a faculty appointment as a tenure-track assistant professor (or higher rank) at the time of award activation. If not, documentation from their institution must accompany the Letter of Intent indicating they will hold the position of assistant professor (or higher rank) by the time of award activation.

Technology Impact Awards provide up to $100,000 per year for two years. The funds may be used for salary, technical assistance, supplies, capital equipment, or scientific travel. CRI does not provide funds for indirect costs.

Closing date: Letters of Intent: November 15, 2021. Selected applicants will be invited to submit a full research proposal with a submission deadline of March 15.

Further information